2025 年回报股东特别分红 A 股权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利1.33169元（含税），其中 2024 年度权益分派 A 股每股现金 红利 0.98169 元（含税），2025 年回报股东特别分红权益分派 A 股每股现金红利 0.35000 元（含税）。 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/5/20 | － | 2025/5/21 | 2025/5/21 | 差异化分红送转： 是 一、 通过分配方案的股东大会届次和日期 证券代码：603259 证券简称：药明康德 公告编号：临 2025-036 无锡药明康德新药开发股份有限公司2024年度及 2024 年度利润分配方案及 2025 年回报股东特别分红方案（以下简称"本次利 润分配方案"）经无锡药明康德新药开发股份有限公司（以下简称"本公司"或 ...

证券代码：603259 证券简称：药明康德 公告编号：临 2025-037 调整后回购价格上限：2025 年第一次回购股份方案的调整后回购价格上 限为 90.72 元/股（含），2025 年第二次回购股份方案的调整后回购价格上限为 95.91 元/股（含）。 回购价格上限调整起始日期：2025 年 5 月 21 日（权益分派除权除息日）。 一、回购股份的基本情况 （一）2025 年第一次回购股份方案 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 无锡药明康德新药开发股份有限公司 调整前回购价格上限：无锡药明康德新药开发股份有限公司（以下简称 "公司"）2024 年年度股东大会审议通过的《关于 2025 年以集中竞价交易方式 回购公司 A 股股份的议案》项下的回购方案（以下简称"2025 年第一次回购股 份方案"）的调整前回购价格上限为 92.05 元/股（含），公司第三届董事会第二 十次会议审议通过的《关于 2025 年第二次以集中竞价交易方式回购公司 A 股股 份的议案》项下的回购方案（以下简称"2025 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不對因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 有關實施2024年度利潤分配及2025年特別股息分派後調整A股 回購價格上限的公告 茲提述(i)無錫藥明康德新藥開發股份有限公司（「本公司」）於2025年3月17日、 2025年4月8日及2025年5月6日刊發的公告（「該等公告」）；(ii)本公司於2025年3 月26日刊發的通函（「通函」）；(iii)於2025年3月26日刊發的2024年股東週年大會 （「2024年股東週年大會」）通告（「股東週年大會通告」）；及(iv)於2025年4月29日 刊發的2024年股東週年大會投票結果公告（「投票結果公告」），內容有關（其中 包括）2025年以集中競價交易方式回購本公司A股股份方案（「2025年首次股份回 購方案」）、2025年第二次以集中競價交易方式回購本公司A ...

药明康德（603259）公告，公司2024年度及2025年回报股东特别分红A股权益分派方案已获股东大会通 过。A股每股现金红利1.33元(含税)，其中2024年度权益分派A股每股现金红利0.98169元(含税)，2025年 回报股东特别分红权益分派A股每股现金红利0.35元(含税)。股权登记日为2025年5月20日，除权(息)日 及现金红利发放日为2025年5月21日。公司A股总股本为25.01亿股，扣除回购专用证券账户中的A股股 份285.59万股，本次实际参与分配的公司A股股份总数为24.98亿股。 ...

Core Insights - The top three companies with the highest short positions are WuXi AppTec (02359), Vanke Enterprises (02202), and Ganfeng Lithium (01772) with short ratios of 16.40%, 14.71%, and 13.17% respectively [1][2] - The company with the largest increase in short positions is Vanke Enterprises (02202), which saw an increase of 1.37% from the previous report [1][2] - Ganfeng Lithium (01772) experienced the largest decrease in short positions, with a reduction of 0.88% [1][3] Short Position Summary - **Top 3 Companies by Short Ratio** - WuXi AppTec (02359): 6,349.45 million shares, 16.40% [2] - Vanke Enterprises (02202): 325 million shares, 14.71% [2] - Ganfeng Lithium (01772): 5,313.62 million shares, 13.17% [2] - **Companies with Largest Increase in Short Positions** - Vanke Enterprises (02202): Increased from 13.34% to 14.71% [2] - COSCO Shipping Holdings (01919): Increased from 12.27% to 13.14% [2] - Yao Cai Securities (01428): Increased from 1.28% to 2.09% [2] - **Companies with Largest Decrease in Short Positions** - Ganfeng Lithium (01772): Decreased from 14.05% to 13.17% [3] - Horizon Robotics-W (09660): Decreased from 1.87% to 1.02% [3] - Hisense Home Appliances (00921): Decreased from 10.94% to 10.14% [3]

Core Viewpoint - The CSI Hong Kong Stock Connect Medical Theme Index has shown significant growth, with a 14.60% increase over the past month and a 17.07% increase year-to-date, reflecting strong performance in the medical sector within the Hong Kong stock market [1][2]. Group 1: Index Performance - The CSI Hong Kong Stock Connect Medical Theme Index rose by 0.59% to 787.2 points, with a trading volume of 16.351 billion yuan [1]. - The index has increased by 10.23% over the past three months [1]. Group 2: Index Composition - The index comprises 50 listed companies involved in medical devices, medical services, pharmaceuticals, and biotechnology [1]. - The top ten weighted stocks in the index include WuXi Biologics (16.41%), JD Health (10.86%), and Alibaba Health (7.38%) [1]. Group 3: Sector Allocation - The sector allocation of the index shows that medical services and commercial services account for 34.97%, while pharmaceuticals and biotechnology services account for 31.72% [2]. - Medical devices represent 12.28%, chemical drugs 10.50%, biological drugs 10.12%, and traditional Chinese medicine 0.42% of the index [2]. Group 4: Index Adjustment Mechanism - The index samples are adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December [2]. - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [2].

Core Viewpoint - The biopharmaceutical industry faces significant uncertainties in 2025, including tariffs, FDA layoffs, and patent expirations, yet opportunities exist amidst these challenges. WuXi AppTec demonstrates resilience with strong financial performance, indicating its ability to navigate uncertainties effectively [1][2]. Financial Performance - WuXi AppTec reported a total revenue of 9.655 billion yuan, a year-on-year increase of 21.0% [2] - Adjusted non-IFRS net profit reached 2.68 billion yuan, reflecting a 40% year-on-year growth, with a non-IFRS net profit margin of 27.7% [2][3] - The company's order backlog increased to 52.33 billion yuan, a 47.1% year-on-year rise, showcasing client confidence in its services [2][3] Market Position and Strategy - WuXi AppTec achieved revenue growth of 28.4% in the US and 26.2% in Europe, surpassing 2024 levels, indicating strong competitiveness in developed markets [3] - The company maintains its annual performance guidance, expecting a revenue growth of 10% to 15% for 2025, targeting total revenue between 41.5 billion and 43 billion yuan [3][4] - Morgan Stanley and Goldman Sachs have raised profit forecasts for WuXi AppTec, reflecting better-than-expected performance in TIDES and small molecule R&D [4] Business Model and Operational Strength - The "CRDMO" model has proven its value, allowing WuXi AppTec to cover the entire drug development chain efficiently, which is crucial in a volatile environment [5][6] - The company has expanded its peptide production capacity significantly, with plans to increase the total volume of solid-phase synthesis reactors to over 100,000 liters by the end of 2025 [8][9] - WuXi AppTec's TIDES business generated 2.24 billion yuan in Q1 2025, a remarkable 187.6% increase year-on-year, with a backlog growth of 105.5% [7][8] Shareholder Returns and Capital Management - WuXi AppTec has returned over 11.3 billion yuan to shareholders in the past three years, with more than 70% of free cash flow directed towards investor returns [9][10] - The company has initiated multiple share buyback programs, totaling 3 billion yuan, reflecting strong management and strategic choices [10]

Summary of the Conference Call Industry Focus - The report focuses on the pharmaceutical industry, specifically highlighting innovative drugs and contract research organizations (CXO) Core Insights and Arguments - Continuous recommendation of innovative drugs with positive growth outlook, including: - 恒瑞医药 (Hengrui Medicine) - 华东医药 (East China Pharmaceutical) - 翰森制药 (Hansoh Pharmaceutical) - 贝达药业 (Betta Pharmaceuticals) - 信立泰 (Sinopharm) - 科伦药业 (Kelun Pharmaceutical) - 百利天恒 (Baili Tianheng) - 荣昌生物 (Rongchang Biopharmaceutical) - 科伦博泰生物 (Kelun Biotech) - 石药集团 (Shijiazhuang Pharmaceutical Group) [1][1][1] - Recommendation of CXOs showing signs of profit growth turning points, including: - 药明生物 (WuXi Biologics) - 药明康德 (WuXi AppTec) [1][1] - Positive outlook on domestic replacement of innovative medical devices, specifically: - 惠泰医疗 (Huitai Medical) [1] - Anticipation of recovery in consumer healthcare, particularly: - 爱尔眼科 (Aier Eye Hospital) [1] Other Important Points - The report emphasizes the ongoing trend of recommending companies that are positioned well within the pharmaceutical sector, particularly those that are expected to benefit from market dynamics and growth opportunities - The focus on innovative drugs and CXOs indicates a strategic approach to capitalize on emerging trends in the healthcare market - The mention of domestic replacements in medical devices suggests a shift towards local production and innovation, which could impact market competition and supply chains - The recovery in consumer healthcare points to potential growth areas as the market stabilizes post-pandemic

Core Viewpoint - WuXi AppTec's stock closed at 58.25 yuan, down 3.46%, with a rolling PE ratio of 15.05 times and a total market capitalization of 168.23 billion yuan [1] Company Summary - WuXi AppTec provides integrated, end-to-end drug development and manufacturing services for the global pharmaceutical and life sciences industries [1] - The company's main business segments include chemical services, testing services, and biological services [1] - For Q1 2025, WuXi AppTec reported revenue of 9.655 billion yuan, a year-on-year increase of 20.96%, and a net profit of 3.672 billion yuan, a year-on-year increase of 89.06%, with a gross profit margin of 42.26% [1] Industry Summary - The average PE ratio for the medical services industry is 38.69 times, with a median of 38.36 times, placing WuXi AppTec at 17th in the industry ranking [1][2] - As of Q1 2025, 385 institutions held shares in WuXi AppTec, including 378 funds, with a total shareholding of 1,109.79 million shares valued at 74.711 billion yuan [1]

恒生指数收盘涨0.13%，恒生科技指数跌0.75%。医药股跌幅居前，百济神州跌近8%，药明生物跌近 7%，药明康德跌近3%。南向资金净卖出78.66亿元。 ...